Nebojša Ignjatović, Goran Stanojević, Miroslav Stojanović, Ljiljana Jeremić, Milica Nestorović, Vesna Brzački, Daniela Benedeto Stojanov, Miodrag Djordjević, Mirjana Marinković

DOI Number
First page
Last page


Patients with advanced gastric cancer generally have poor overall prognosis as well as survival rate. Unfortunately, in the West, gastric cancer typically occurs at an advanced stage and many of these patients have tumor invasion into adjacent structures (International Union Against Cancer [UICC]/American Joint Committee on Cancer [AJCC] Stage T4). Although T4 gastric cancer patients often have peritoneal dissemination or distant metastasis, many do not have M1 disease and are therefore candidates for surgery with the curative intent. A multivisceral resection (MVR) or gastrectomy with resection of adjacent organs is needed in T4 gastric cancer patients to achieve an R0 resection that is one of the most powerful forecasters of gastric cancer surgery results. Spleen, distal pancreas, liver, and large intestine (mostly transverse colon) were the most commonly resected organs. The therapeutic choice with acceptable postoperative morbidity and mortality rates in locally advanced patients with gastric cancer should be gastrectomy with MVR, where complete resection could be realistically obtained and where metastatic involvement of the lymph node is not evident. MVR is done with a curative R0 resection to provide advanced gastric cancer patients with the best survival chance. It was found that resections involving the pancreas, transverse colon and liver were associated with increased survival rate in comparison to MVR with resection of other structures. It was shown that survival rate significantly decreased in patients who had undergone MVR without complete resection compared to those who had an R0 resection. Nevertheless, the extent of the surgical resection required and further advantages of MVR are disputable.


advanced gastric cancer, gastrectomy, multivisceral resection

Full Text:



Van de Velde CJH. Gastric cancer: staging and surgery. Ann Oncol 2002; 13 Suppl 4:1–6.

Kim JH, Jang YJ, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS. Surgical outcomes and prognostic factors for T4 gastric cancers. Asian J Surg 2009; 32:198–204.

Yamamoto M, Rashid OM, Wong J. Surgical management of gastric cancer: the East vs. West perspective. J Gastrointest Oncol 2015; 6:79–88.

Marano L, Polom K, Patriti A, et al. Surgical management of advanced gastric cancer: An evolving issue. Eur J Surg Oncol 2016; 42:18–27.

Lee HC, Yang MT, Lin KY, Tu HY, Zhang TA, Chen PH. Metastases from gastric carcinoma to colon in the form of multipleflat elevated lesions: a case report. Kaohsiung J Med Sci 2004; 20:552–527.

Weledji EP. How surgery can improve multimodal treatment of gastric cancer. In: Management of Gastric Cancer. Group SM, 2016: 1–12.

Ikeguchi M, Kader A, Takaya S, et al. Treatment of patients with stage IV gastric cancer. J Gastrointest Cancer 2013; 44:199–202.

Brar SS, Seevaratnam R, Cardoso R, Yohanathan L, Law C, Helyer L, Coburn NG. Multivisceral resection for gastric cancer: a systematic review. Gastric Cancer 2012; 15 Suppl 1:S100–7.

Lim S. Muhs BE, Marcus SG, Newman E, Berman RS, Hiotis SP. Results following resection for stage IV gastric cancer; are better outcomes observedin selected patient subgroups? J Surg Oncol 2007; 95:118–122

Kasakura Y, Fujii M, Mochizuki F, Kochi M, Kaiga T. Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer? Am J Surg 2000; 179:237–242.

Pacelli F, Cusumano G, Rosa F, et al. Italian Research Group for Gastric Cancer. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA Surg 2013; 148:353–360.

Li MZ, Deng L, Wang JJ, et al. Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One 2014; 9:e107061

Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347:995–999.

Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002; 236:159–165



  • There are currently no refbacks.

ISSN 0354-2017 (Print)

ISSN 2406-0526  (Online)